Food and Drug Administration
Cardiovascular & Renal Drugs Advisory Committee
January 17, 2002
NDA 20-757/S-021 Avapro® (irbesartan), Sanofi-Synthelabo (c/o Bristol-Myers squibb), for the treatment of hypertensive patients with tyep 2 diabetic renal disease
Briefing Information
Disclaimer
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
Sponsor Briefing Information
Bristol-Myers Squibb Pharmaceutical Research Institute, Sanofi-Synthelabo pdf
Food and Drug Administration
Medical Review pdf
Statistical Review pdf htm doc